Chicago-based Lumere, a leading provider of evidence-based data and analytics solutions, has five suggestions for what healthcare executives need to know about the biosimilars. read more

The Lumere acquisition by GHX was part of a round-up of digital health investments made in Q1-2020. The blog notes the Lumere acquisition is one of "the quarter’s main deals.” read more

Sam Bastow, PharmD, Lumere Pharmacy Solution Advisor, comments on FDA approval of remdesivir on an emergency basis for the treatment of COVID-19. read more

The shortage of ventilators during COVID-19 has been reported, but pharmacists are now sounding the alarm on a possible shortage of drugs needed for ventilated patients. read more

Karen Conway of GHX and Dr. John Cherf of Lumere weigh in on the importance of collaboration between supply chain and critical care clinicians during COVID-19, and also share insight into how the pandemic will impact the future of the healthcare supply chain. read more

Lumere is offering complimentary access through April 30, 2020, to its evidence-based research on drugs and devices, including a quick reference list of COVID-19 related supplies with potential shortages. read more

Industry leaders including Lumere's Chief Medical Officer and Value Analysis Solution Advisor weigh in on whether the industry has achieved true clinical integration, best practice strategies and tactics to establish short- and long-term integration and how organizations can mature. read more

There is a long history of innovation in supplemental technology for joint arthroplasty procedures, from the early intramedullary cutting jig decades ago to today’s digital soft-tissue balancers, computer navigation, and robotics. read more

In March 2019, the FDA approved the brexanolone (Zulresso, Sage Therapeutics) injection for intravenous (IV) use for the treatment of PPD in adult women. This was the first drug approved by the FDA specifically for this disorder. read more